Comprehensive Monograph on Orphenadrine (DB01173)

Executive Summary and Introduction

Orphenadrine is a centrally acting skeletal muscle relaxant with a long and complex history in clinical medicine. Developed in the 1940s and first approved for use in the United States in 1957, it is a structural analog of the first-generation antihistamine diphenhydramine, distinguished by the addition of a methyl group to one of its phenyl rings.[1] Its primary therapeutic indication is as an adjunctive treatment for the relief of pain and discomfort associated with acute, painful musculoskeletal conditions, such as muscle strains and sprains.[3] Historically, it also played a significant role in the management of motor symptoms, particularly tremor and rigidity, in Parkinson's disease and drug-induced parkinsonism, although this use has largely been superseded by more effective and better-tolerated agents.[1]

The pharmacological profile of orphenadrine is multifaceted, leading to its characterization as a "dirty drug" due to its engagement with multiple receptor systems.[1] Its clinical effects are derived from a combination of three distinct mechanisms: potent central anticholinergic (muscarinic antagonist) activity, histamine H1 receptor antagonism, and non-competitive N-methyl-D-aspartate (NMDA) receptor antagonism.[8] This complex profile is responsible for its therapeutic benefits but also underlies its significant and often dose-limiting side effect burden.

The continued clinical application of orphenadrine, an agent developed over 70 years ago with a well-documented and challenging safety profile, presents a notable therapeutic paradox. Its persistence in the pharmacopeia, despite being largely superseded by newer drugs and carrying significant risks, suggests it may fill a specific clinical niche not adequately addressed by more selective agents.[1] The drug's safety profile is marked by a prominent anticholinergic burden, high toxicity in overdose, a recognized potential for abuse, and numerous contraindications that limit its use in many patient populations.[1] Regulatory bodies have acknowledged these risks; for instance, Australia's Therapeutic Goods Administration (TGA) rejected a proposal to make a low-dose combination product available without a prescription, citing safety concerns.[13] Nevertheless, orphenadrine remains in use and is even the subject of contemporary clinical investigation for novel applications such as bruxism and muscle cramps associated with liver cirrhosis.[15] This apparent contradiction suggests that its multi-modal mechanism of action—simultaneously targeting muscarinic, histaminic, and NMDA receptors—may offer a unique therapeutic advantage for complex pain syndromes where muscle spasm, central sensitization, and other neurological components coexist. While problematic from a side-effect perspective, this multi-target engagement might provide a broader spectrum of relief than highly selective agents, thereby explaining its enduring, albeit limited, role in medicine. This report provides a comprehensive, evidence-based monograph on orphenadrine, synthesizing its chemistry, pharmacology, clinical applications, and safety profile to inform its appropriate use in contemporary practice.

Physicochemical Properties and Formulations

Chemical Identification and Structure

Orphenadrine is chemically classified as a tertiary amino compound and an ether.[8] Its systematic International Union of Pure and Applied Chemistry (IUPAC) name is N,N-dimethyl-2-[(2-methylphenyl)-phenylmethoxy]ethanamine.[8] It is widely known by a variety of synonyms, including o-Methyldiphenhydramine, 2-Methyldiphenhydramine, Disipal, and Norflex.[8] Structurally, it is the phenyl-o-tolylmethyl ether of 2-(dimethylamino)ethanol and is a direct derivative of diphenhydramine, differing by the presence of a methyl group on the ortho position of one of the phenyl rings.[1]

The base molecule possesses the molecular formula $C_{18}H_{23}NO$ and has a molecular weight of approximately 269.4 g/mol.[8] The compound is chiral and is used clinically as a racemic mixture of its (±) enantiomers.[21] For unambiguous identification across various scientific and regulatory databases, a consolidated list of key identifiers is provided in Table 1.

Table 1: Key Chemical and Drug Identifiers for Orphenadrine

Identifier Type	Value	Source(s)
CAS Number	83-98-7	[8, 19]
DrugBank ID	DB01173	[8, 19]
PubChem CID	4601	1
InChI	InChI=1S/C18H23NO/c1-15-9-7-8-12-17(15)18(20-14-13-19(2)3)16-10-5-4-6-11-16/h4-12,18H,13-14H2,1-3H3	1
InChIKey	QVYRGXJJSLMXQH-UHFFFAOYSA-N	1
SMILES	CC1=CC=CC=C1C(C2=CC=CC=C2)OCCN(C)C	8
UNII	AL805O9OG9	[8, 9]
ChEBI ID	CHEBI:7789	8
ATC Codes	M03BC51, N04AB02, M03BC01	[9, 19]

Physical and Chemical Properties

The physical state of orphenadrine varies depending on whether it is in its base or salt form. The free base is described as a liquid with a melting point below 25°C and a boiling point of 195°C at 12 mm Hg.[8] In contrast, its clinically used salt forms, citrate and hydrochloride, are typically white, crystalline powders that are practically odorless and have a characteristic bitter taste.[5]

The solubility profile is critical for its formulation and administration. Orphenadrine free base is sparingly soluble in water.[8] The citrate salt is also sparingly soluble in water (≥5.74 mg/mL with sonication) and slightly soluble in alcohol, but it is soluble in acidic solutions.[5] The hydrochloride salt exhibits greater aqueous solubility (~10 mg/mL in PBS) and is also soluble in alcohol and chloroform, while being practically insoluble in ether.[8] Both salts are highly soluble in organic solvents such as dimethyl sulfoxide (DMSO) and dimethylformamide (DMF).[25] The melting point of the hydrochloride salt is in the range of 160–164°C.[27]

Available Formulations and Salt Forms

Orphenadrine is commercially available as two primary salt forms: citrate and hydrochloride.[1]

• Orphenadrine Citrate: This is the most common form in many regions, including the United States. It is marketed under brand names such as Norflex® and is a component of combination products like Norgesic®.[1] It is available as standard tablets, extended-release tablets, and as a solution for injection.[1] The molecular formula of the citrate salt is $C_{24}H_{31}NO_{8}$, with a corresponding molecular weight of 461.5 g/mol.[29]
• Orphenadrine Hydrochloride: This salt form is marketed under the brand name Disipal®.[1] Its molecular formula is $C_{18}H_{23}NO \cdot HCl$, with a molecular weight of 305.84 g/mol.[27]

Orphenadrine is frequently co-formulated with other therapeutic agents to provide multi-modal pain relief. Common combination products include:

• With Aspirin and Caffeine: Marketed as Norgesic® and Orphengesic®, these formulations combine the muscle relaxant properties of orphenadrine with the analgesic and anti-inflammatory effects of aspirin and the stimulant effect of caffeine to counteract sedation.[1]
• With Paracetamol (Acetaminophen): Available in some regions, these products combine orphenadrine with the analgesic and antipyretic paracetamol.[12]
• With Ibuprofen: Formulations combining orphenadrine with the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen are also available.[1]

Clinical Pharmacology

The classification of orphenadrine simply as a "skeletal muscle relaxant" is a significant oversimplification that can obscure a nuanced understanding of its clinical utility and risks. Multiple sources confirm that orphenadrine does not directly relax skeletal muscle tissue.[5] Instead, its therapeutic action is attributed to its analgesic properties and its ability to centrally alter the body's perception of muscle pain.[4] Its diverse mechanisms of action—anticholinergic, antihistaminic, and NMDA antagonism—all function to modulate central nervous system activity and pain processing pathways.[8] Therefore, a more accurate framework is to view orphenadrine as a centrally acting neuromodulator with analgesic properties, whose effects on muscle spasm are secondary to its broader impact on central pain processing. This recontextualization better explains its efficacy in conditions like tension headaches, its potential in neuropathic-like states, and the profound CNS side effects observed in therapy and overdose, providing a more precise guide for clinical application and risk management.[38]

Mechanism of Action: A Multi-Target Profile

The therapeutic action of orphenadrine is not fully elucidated but is understood to be centrally mediated and arises from its complex interaction with multiple neurotransmitter systems rather than a direct effect on muscle fibers.[2]

Anticholinergic (Antimuscarinic) Activity

Orphenadrine is a potent, nonselective muscarinic antagonist with predominantly central nervous system effects and only weak peripheral action.[1] Its anticholinergic potency has been estimated to be 58% that of atropine.[1] This activity is believed to block facilitatory functions within the brain stem's reticular formation, thereby interfering with the transmission of nerve impulses from the spinal cord to muscles and reducing muscle hypertonia and spasm.[40] This same mechanism is responsible for its therapeutic effect in Parkinson's disease, where a deficiency in dopamine leads to a relative overactivity of the cholinergic system; orphenadrine helps restore this neurochemical balance.[3] Critically, this potent anticholinergic action is also the primary source of the drug's characteristic and often dose-limiting adverse effects.[1]

Histamine H1 Receptor Antagonism

As a chemical derivative of the first-generation ethanolamine antihistamine diphenhydramine, orphenadrine retains antagonist properties at the histamine H1 receptor.[1] Although its antihistaminic activity is considered weaker than that of its parent compound, it contributes to the overall pharmacological profile, including its sedative potential.[43] A molecular docking study suggested that orphenadrine has a binding affinity for the H1 receptor that is comparable to that of diphenhydramine.[45]

NMDA Receptor Antagonism and Neuroprotective Potential

A key and perhaps underappreciated aspect of orphenadrine's mechanism is its function as a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist.[8] It binds to the phencyclidine (PCP) site located within the receptor's ion channel.[10] Orphenadrine is characterized as a "mild" or low-affinity antagonist, with a dissociation constant ($K_i$) of approximately 6 µM and fast open-channel blocking kinetics.[9] This specific kinetic profile is clinically significant; it allows the drug to preferentially block the pathological, sustained, low-level activation of NMDA receptors associated with excitotoxicity and central sensitization, while still permitting the rapid, physiological glutamatergic transmission necessary for normal synaptic function. This distinguishes it from high-affinity channel blockers like PCP, which cause significant psychotomimetic side effects by indiscriminately blocking the channel.[37] Preclinical studies have demonstrated that this mechanism confers neuroprotective effects, shielding neurons from excitotoxic cell death and suggesting a potential therapeutic role in neurodegenerative disorders mediated by NMDA receptor overactivation.[10]

Pharmacodynamics

The clinical effects of orphenadrine are a direct consequence of its multi-target engagement. The primary muscle relaxant effect is centrally mediated, likely through its anticholinergic actions on cerebral motor centers in the brain stem and medulla.[8] Its analgesic properties may be further enhanced by its activity as a noradrenaline reuptake transporter inhibitor and its local anesthetic properties.[7] The mood-elevating or euphoric effects that have been reported, which contribute to its potential for abuse, may be linked to its central anticholinergic and/or NMDA antagonist activities.[7]

Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of orphenadrine is characterized by rapid and complete absorption, extensive distribution, significant hepatic metabolism, and a moderately long elimination half-life. A summary of key parameters is provided in Table 2.

Absorption and Bioavailability

Orphenadrine is readily and almost completely absorbed from the gastrointestinal tract after oral administration and is also rapidly absorbed following intramuscular (IM) injection.[7] The oral bioavailability is high, reported to be between 90% and 95%.[1] The onset of therapeutic action is relatively rapid: within one hour following an oral dose, approximately five minutes after an IM injection, and almost immediately upon intravenous (IV) administration.[45] Peak plasma concentrations ($T_{max}$) are typically reached 2 to 4 hours after oral ingestion.[43]

Distribution and Protein Binding

Following absorption, orphenadrine is rapidly and widely distributed throughout the body's tissues.[34] This extensive tissue retention, particularly in highly perfused organs such as the lungs, leads to a slow release of the drug back into the bloodstream.[34] Orphenadrine is highly bound to plasma proteins, with a binding fraction of approximately 95%.[1] The drug is presumed to cross the placental barrier and is known to be excreted in breast milk, leading to recommendations against its use during pregnancy and lactation.[3]

Hepatic Metabolism and Active Metabolites

Orphenadrine undergoes extensive biotransformation in the liver, where it is converted into at least eight different metabolites.[34] This process is primarily mediated by the cytochrome P450 (CYP450) enzyme system.[1] Orphenadrine is a minor substrate of CYP1A2, CYP2B6, CYP2D6, and CYP3A4 and also acts as a weak inhibitor of several CYP isoenzymes, including CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2E1, and CYP3A4, creating a potential for drug-drug interactions.[9] Two of its metabolites, N-demethyl orphenadrine and N,N-didemethyl orphenadrine, are known to be pharmacologically active.[7]

Elimination and Half-Life

The primary route of elimination for orphenadrine and its metabolites is through the kidneys, with the majority excreted in the urine.[34] A small proportion of the drug is excreted unchanged.[44] Biliary excretion also contributes to its clearance.[1] The elimination half-life ($t_{1/2}$) is reported with some variability across studies, generally falling within the range of 13 to 20 hours.[1] An average half-life of 14 hours is frequently cited, which classifies it as an intermediate-acting drug and supports a twice-daily dosing regimen to maintain stable therapeutic concentrations.[22]

Table 2: Summary of Pharmacokinetic Parameters for Orphenadrine

Parameter	Value	Source(s)
Bioavailability (Oral)	90–95%	1
Onset of Action	Oral: ~1 hour; IM: ~5 minutes; IV: Immediate	45
Time to Peak Plasma Concentration ($T_{max}$)	2–4 hours	43
Protein Binding	~95%	1
Primary Metabolism	Hepatic (CYP450 system)	1
Active Metabolites	N-demethyl orphenadrine, N,N-didemethyl orphenadrine	7
Primary Route of Excretion	Renal (primarily as metabolites)	[34, 43]
Elimination Half-Life ($t_{1/2}$)	13–20 hours (Average: ~14 hours)	[1, 43, 44]

Therapeutic Applications

Approved Indications and Efficacy

Acute Painful Musculoskeletal Conditions

The primary approved indication for orphenadrine is as an adjunctive therapy for the relief of discomfort associated with acute, painful musculoskeletal conditions.[3] It is intended to be used in combination with rest, physical therapy, and other measures to treat pain arising from muscle strains, sprains, and other injuries.[4] It is particularly claimed to be useful for conditions where muscle spasm is a prominent component of the pain, such as lower back ache, whiplash injuries, and sports-related muscle trauma.[12]

The efficacy of orphenadrine for these conditions is considered established but modest. A 2004 systematic review concluded there was "fair evidence" supporting its effectiveness for acute back or neck pain, but found insufficient data to determine its efficacy relative to other muscle relaxants.[1] Its overall benefit is generally described as modest.[12] There is no evidence to support its use for pain arising from rheumatoid arthritis.[1]

Parkinson's Disease and Drug-Induced Parkinsonism

Historically, orphenadrine was a mainstay in the management of Parkinson's disease.[1] It is still used today, though less commonly, to alleviate motor symptoms such as tremor and rigidity associated with both idiopathic Parkinson's disease and drug-induced extrapyramidal syndromes.[3] A Cochrane Review of anticholinergic drugs for Parkinson's disease found that the class as a whole is useful, providing benefit to approximately 20% of patients.[1] However, orphenadrine and other anticholinergics have been largely superseded by more effective dopaminergic therapies, and their use is often limited by their significant anticholinergic side effects.[1]

Role in Combination Therapy

Orphenadrine is frequently utilized in fixed-dose combination products to provide multi-modal analgesia. The most common formulation combines orphenadrine citrate with aspirin and caffeine, available under brand names such as Norgesic® and Orphengesic®.[1] These products are indicated for the symptomatic relief of mild-to-moderate pain associated with acute musculoskeletal disorders.[42] The therapeutic rationale is based on the synergistic actions of the components: orphenadrine provides central muscle relaxation, aspirin offers analgesic and anti-inflammatory effects, and caffeine helps to counteract the potential for sedation.[12] Other available combinations include formulations with paracetamol (acetaminophen), ibuprofen, or mefenamic acid.[7]

Off-Label and Investigational Uses

Beyond its approved indications, orphenadrine has been used for other conditions and is the subject of ongoing clinical research.

• Tension Headaches and Hiccoughs: Product information materials have noted its value in treating tension headaches and persistent hiccoughs.[38]
• Muscle Cramps in Liver Cirrhosis: A pilot study involving patients with liver cirrhosis demonstrated that orphenadrine (100 mg twice daily) was safe and significantly more effective than a control treatment in reducing the frequency, duration, and severity of painful muscle cramps. The beneficial effects were observed to persist even after a two-week washout period.[16]
• Bruxism and Orofacial Pain: A Phase 4 clinical trial (NCT07109882) is actively recruiting participants to evaluate the effectiveness of orphenadrine citrate compared to chlorzoxazone for alleviating pain associated with bruxism.[15]
• Postoperative Pain: A completed Phase 4 clinical trial (NCT04835116) investigated the use of orphenadrine as part of a multi-drug regimen for providing analgesia following percutaneous nephrolithotomy.[54]

Dosing, Administration, and Special Populations

Dosage Forms and Strengths

Orphenadrine is available in several dosage forms and strengths, both as a single agent and in combination products.

• Oral Formulations:
• Extended-Release (ER) Tablets: Containing 100 mg of orphenadrine citrate.[39]
• Immediate-Release (IR) Tablets: Containing 50 mg of orphenadrine.[3]
• Combination Tablets:
• Norgesic®: 25 mg orphenadrine citrate, 385 mg aspirin, and 30 mg caffeine.[34]
• Norgesic Forte®: 50 mg orphenadrine citrate, 770 mg aspirin, and 60 mg caffeine.[19]
• Paracetamol Combination: 35 mg orphenadrine citrate and 450 mg paracetamol.[32]
• Parenteral Formulation:
• Solution for Injection: Supplied at a concentration of 30 mg/mL, typically in 2 mL ampuls or vials containing a total of 60 mg of orphenadrine citrate for intravenous (IV) or intramuscular (IM) administration.[5]

Recommended Dosing Regimens

Dosage regimens for adults vary based on the indication and formulation.

• For Muscle Spasm (Adults):
• Oral Extended-Release: The standard dose is 100 mg taken twice daily, once in the morning and once in the evening.[3]
• Oral Immediate-Release: The typical dose is 50 mg taken three times a day.[3]
• Parenteral (IV/IM): For acute situations, 60 mg is administered every 12 hours as needed. Parenteral therapy should be transitioned to an oral formulation as soon as clinically feasible.[55]
• Administration Guidelines:
• Oral: Extended-release tablets must be swallowed whole and should not be crushed, broken, or chewed.[3] The tablets can be taken with or without food.[58]
• Intravenous (IV): The injection should be administered slowly over approximately 5 minutes with the patient in a supine position. The patient should remain lying down for 5–10 minutes post-injection to minimize the risk of dizziness or fainting.[34]
• Intramuscular (IM): The injection should be administered deeply into a large muscle mass.[58]

Considerations in Special Populations

• Geriatric Patients: Orphenadrine should be used with significant caution in elderly patients. This population is more susceptible to the drug's anticholinergic side effects, including confusion, dizziness, sedation, and falls.[3] Dose reduction should be considered.[48] Furthermore, the cumulative and continuous use of strong anticholinergic drugs like orphenadrine is associated with an increased risk of long-term cognitive decline and dementia.[1] Consequently, it is not recommended as a first-line treatment option for older adults.[63]
• Pediatric Patients: The safety and efficacy of orphenadrine have not been established in children. Its use and dosage in this population must be determined by a physician.[3] It is generally not recommended for children under 12 years of age.[38]
• Pregnancy and Lactation: Orphenadrine is classified as Pregnancy Category C in the United States, as its safety during pregnancy has not been established. It should only be used if the potential benefit to the mother justifies the potential risk to the fetus.[5] The drug is excreted in breast milk, and its use is not recommended in nursing mothers.[3]
• Renal and Hepatic Impairment: Caution is advised when administering orphenadrine to patients with impaired kidney or liver function.[3] However, specific guidelines for dose adjustments in these populations have not been established.[58]

Safety Profile and Toxicology

Adverse Drug Reactions

The adverse effects of orphenadrine are predominantly linked to its anticholinergic (antimuscarinic) properties and tend to be more frequent and severe at higher dosages.[23] Dry mouth is characteristically the first and most common side effect to appear.[1] A comprehensive list of adverse reactions is organized by system organ class in Table 3.

Table 3: Common and Serious Adverse Reactions to Orphenadrine by System Organ Class

System Organ Class	Adverse Reaction	Reported Incidence	Source(s)
Neurologic/Psychiatric	Drowsiness, Dizziness, Lightheadedness, Headache, Weakness	Common	[1, 2, 62, 69]
	Confusion, Agitation, Anxiety, Excitement, Irritability, Nervousness, Restlessness	Less Common / Incidence Not Known	[3, 38, 56, 68]
	Hallucinations, Tremor, Syncope, Seizures	Rare / Incidence Not Known	[3, 4, 68, 70]
Cardiovascular	Tachycardia (fast heart rate), Palpitations	Common / Incidence Not Known	[4, 63, 69, 70]
	Fainting	Incidence Not Known	[3, 68]
Gastrointestinal	Dry Mouth, Nausea, Vomiting, Constipation	Common	[1, 2, 62, 63]
	Abdominal or stomach pain, Gastric irritation, Diarrhea	Incidence Not Known	[3, 63, 70]
Genitourinary	Urinary hesitancy or retention	Common / Incidence Not Known	[1, 62, 70, 71]
Ocular	Blurred vision, Mydriasis (dilated pupils)	Common / Less Common	[1, 38, 56, 62]
	Increased intraocular pressure, Glaucoma, Eye pain	Incidence Not Known	[3, 51, 63]
Dermatologic/Hypersensitivity	Skin rash, Hives, Itching (Pruritus)	Rare / Incidence Not Known	[3, 38, 63, 68]
	Anaphylaxis (life-threatening allergic reaction)	Rare	[3, 46, 68, 70]
Hematologic	Aplastic anemia	Very Rare	[23, 58, 69, 70]

Contraindications

Due to its significant anticholinergic effects, orphenadrine is strictly contraindicated in patients with the following conditions:

• Glaucoma, particularly narrow-angle glaucoma.[1]
• Gastrointestinal obstruction, such as pyloric or duodenal obstruction, stenosing peptic ulcers, or bowel obstruction.[1]
• Genitourinary obstruction, including prostatic hypertrophy or bladder neck obstruction.[1]
• Myasthenia gravis.[1]
• Cardiospasm (megaesophagus) or achalasia.[5]
• Known hypersensitivity to orphenadrine or any component of the formulation.[5]

Warnings and Precautions

• Central Nervous System (CNS) Effects: Orphenadrine can cause transient episodes of light-headedness, dizziness, drowsiness, or syncope. It may significantly impair the mental and physical abilities required for performing potentially hazardous tasks such as driving a motor vehicle or operating machinery. Patients should be cautioned accordingly.[5]
• Cardiac Conditions: The drug should be used with caution in patients with pre-existing cardiac conditions, including tachycardia, cardiac decompensation, coronary insufficiency, or cardiac arrhythmias, as it may exacerbate these conditions.[5]
• Cognitive Effects and Dementia Risk: As a strong anticholinergic agent, the continuous and cumulative use of orphenadrine is associated with an increased risk of cognitive decline and incident dementia, a risk that is particularly pronounced in the elderly population.[1]
• Long-Term Use: The safety of continuous long-term therapy has not been established. For patients prescribed orphenadrine for prolonged periods, periodic monitoring of blood, urine, and liver function is recommended.[5]
• Sulfite Sensitivity: The injectable formulation of orphenadrine contains sodium bisulfite, which can trigger severe allergic-type reactions, including anaphylaxis and life-threatening asthmatic episodes, in susceptible individuals. This sensitivity is seen more frequently in people with asthma.[5]

Overdose Management and Toxicity

Orphenadrine is highly toxic in overdose and possesses a narrow therapeutic index.[12] The minimum lethal dose in adults is estimated to be between 2 and 3 grams.[46] Evidence suggests that orphenadrine is more toxic in overdose than other anticholinergic drugs and is disproportionately represented in overdose fatalities.[12]

• Symptoms of Overdose: The clinical presentation of orphenadrine overdose is a severe anticholinergic toxidrome. Symptoms include profound CNS toxicity (confusion, delirium, hallucinations, agitation, refractory seizures, and coma), cardiovascular effects (sinus tachycardia, and potentially life-threatening ventricular dysrhythmias), and peripheral anticholinergic signs (mydriasis, blurred vision, flushed skin, dry mouth, and urinary retention).[3] Complications can include respiratory failure and rhabdomyolysis.[2]
• Management: There is no specific antidote for orphenadrine toxicity; treatment is entirely supportive.[74] Management involves gastric decontamination with activated charcoal if the patient presents within one hour of ingestion, intensive cardiovascular and neurological monitoring, and appropriate supportive care for emergent complications. This may include benzodiazepines for seizures and sodium bicarbonate for cardiac toxicity.[44] Due to the drug's rapid and extensive distribution into tissues, hemodialysis and other extracorporeal removal techniques are generally not effective.[47]

Abuse Potential and Dependence

Orphenadrine has been chronically abused for its mood-elevating and euphoric effects, which can occur even at standard therapeutic doses.[46] While there are case reports documenting dependency and abuse, it is not considered a commonly abused substance.[12] In the United States, orphenadrine is not classified as a federally controlled substance.[59]

Clinically Significant Drug Interactions

Orphenadrine is subject to numerous drug interactions, with over 400 known interactions documented.[76] These are primarily pharmacodynamic in nature, involving additive effects with other CNS depressants and anticholinergic agents. Key interactions are summarized in Table 4.

Interactions with CNS Depressants and Alcohol

The co-administration of orphenadrine with other CNS depressants results in pharmacodynamic synergism, leading to additive CNS depression.[55] This interaction is of major clinical significance.

• Interacting Agents: This class includes alcohol, benzodiazepines (e.g., alprazolam, diazepam), opioids (e.g., fentanyl, hydrocodone), barbiturates, sedating antihistamines, and other muscle relaxants.[3]
• Clinical Effect: The combination can lead to an increased risk of profound sedation, dizziness, impaired judgment, psychomotor impairment, respiratory depression, coma, and potentially death.[55]
• Management: Concurrent use should be avoided if possible. If necessary, it must be undertaken with extreme caution, using the lowest effective doses for the minimum required duration. Patients must be strictly warned against consuming alcohol and counseled about the risks of driving or operating hazardous machinery.[55]

Additive Effects with Anticholinergic Agents

Combining orphenadrine with other drugs that possess antimuscarinic properties leads to additive anticholinergic effects, increasing the overall "anticholinergic burden".[12]

• Interacting Agents: These include tricyclic antidepressants (e.g., amitriptyline), phenothiazines, amantadine, and other medications with significant anticholinergic activity such as benztropine and atropine.[48]
• Clinical Effect: This interaction potentiates the risk and severity of anticholinergic side effects, including severe dry mouth, blurred vision, urinary retention, constipation, tachycardia, and CNS effects like confusion and delirium.[58]
• Management: Therapy should be closely monitored for signs of anticholinergic toxicity. In some cases, such as with the inhaled anticholinergic aclidinium, the combination should be avoided entirely.[49]

Pharmacokinetic and Other Interactions

• Propoxyphene: The concomitant use of orphenadrine and propoxyphene has been associated with reports of confusion, anxiety, and tremors. This is thought to be an additive effect, and dose reduction or discontinuation of one or both agents is recommended if these symptoms occur.[5]
• CYP450 System: As an inhibitor of several CYP450 enzymes, orphenadrine can increase the serum concentrations of other drugs that are metabolized by these pathways (e.g., abemaciclib, acalabrutinib, acebutolol).[7]
• Levodopa: In patients with Parkinson's disease, chronic intake of orphenadrine has been shown to potentially delay and decrease the absorption of levodopa, which could lead to a less predictable and diminished therapeutic response.[83]
• Potassium Chloride: The use of orphenadrine with oral potassium chloride supplements (especially wax-matrix formulations) is not recommended due to the increased risk of esophageal and gastrointestinal lesions. Orphenadrine's anticholinergic effect slows gastrointestinal motility, prolonging the contact time of the potassium tablets with the mucosal lining.[3]

Table 4: Major and Moderate Drug Interactions with Orphenadrine

Interacting Drug/Class	Severity	Mechanism & Potential Effect	Clinical Management	Source(s)
Alcohol & CNS Depressants (Opioids, Benzodiazepines)	Major	Pharmacodynamic synergism; additive CNS and respiratory depression, profound sedation, risk of death.	Avoid combination. If necessary, use lowest doses for shortest duration and monitor closely. Counsel patient on risks.	[55, 79]
Other Anticholinergic Agents (TCAs, Phenothiazines)	Moderate	Additive pharmacodynamic effects; increased anticholinergic burden (confusion, urinary retention, tachycardia).	Monitor closely for signs of anticholinergic toxicity. Consider dose reduction.	[49, 58]
Potassium Chloride (Oral)	Not Recommended	Decreased GI motility from anticholinergic effect increases risk of esophageal/gastric ulceration from potassium tablets.	Avoid combination.	3
Propoxyphene	Moderate	Additive CNS effects leading to confusion, anxiety, and tremors.	Monitor for CNS toxicity. Dose reduction or discontinuation of one or both agents may be necessary.	[5, 56]
Levodopa	Moderate	Pharmacokinetic interaction; delayed and decreased absorption of levodopa.	Monitor for reduced efficacy of levodopa and unpredictable motor response.	83

Regulatory Status and History

Historical Development and Initial Approval

Orphenadrine was discovered and developed in the 1940s at Parke-Davis, emerging from research on antihistamines led by George Rieveschl, who was also instrumental in the development of its parent compound, diphenhydramine.[1] Before the widespread adoption of dopaminergic therapies like levodopa in the late 1960s, anticholinergic drugs such as orphenadrine were a cornerstone of treatment for Parkinson's disease.[1]

In the United States, the Food and Drug Administration (FDA) initially approved the brand name product, Norflex (orphenadrine citrate), as an extended-release tablet on November 2, 1959 (NDA 012157), followed by the approval of the injectable formulation on October 2, 1960 (NDA 013055).[84] Since then, numerous generic versions have been approved, including an Abbreviated New Drug Application (ANDA 040249) for a product from Kiel Laboratories on January 29, 1999, and an approval for Sagent Pharmaceuticals' generic Orphenadrine Citrate Injection in 2011.[85]

Current Regulatory Standing

• United States (FDA): Orphenadrine is a prescription-only (Rx-only) medication and is not scheduled as a controlled substance at the federal level.[59] In December 2022, the FDA officially determined that the original brand-name Norflex products had been withdrawn from the market for commercial reasons, not due to safety or effectiveness concerns. This finding allows the FDA to continue approving generic ANDAs that reference these products.[84]
• Australia (TGA): In Australia, orphenadrine is classified as a Schedule 4 (Prescription Only Medicine) substance.[12] In 2018, the TGA made a final decision not to amend this scheduling, rejecting a proposal to down-schedule a low-dose combination product (35 mg orphenadrine with 450 mg paracetamol) to Schedule 3 (Pharmacist Only Medicine). The decision was based on significant concerns regarding orphenadrine's toxicity in overdose, its potential for abuse, and the judgment that the conditions it treats warrant medical management.[12] The TGA has approved several orphenadrine-containing products, including NORGESIC (orphenadrine/paracetamol, ARTG ID 156623) and NORFLEX (100 mg slow-release tablet, ARTG ID 370413).[33]
• Europe (EMA) & United Kingdom (MHRA): Orphenadrine does not appear to have a centralized marketing authorization from the European Medicines Agency (EMA); instead, it is authorized through national procedures in individual member states.[90] In the UK, for example, an Orphenadrine Hydrochloride 50mg/5ml Oral Solution holds a marketing authorization (PL 00427/0076), first granted in 1990.[44] In 2023, the EMA granted a product-specific waiver for a Paediatric Investigation Plan (PIP) for a combination of diclofenac and orphenadrine for pain treatment, indicating that the product is not being developed for pediatric use in Europe.[91]

Recent Safety Alerts and Recalls

In March 2022, Sandoz Inc. initiated a voluntary nationwide recall in the United States for 13 specific lots of its Orphenadrine Citrate 100 mg Extended-Release tablets. The recall was prompted by the detection of a nitrosamine impurity, N-methyl-N-nitroso-2-[(2-methylphenyl)phenylmethoxy]ethanamine (NMOA), at levels potentially exceeding the FDA's acceptable daily intake limit. Nitrosamine impurities are classified as potential human carcinogens.[56]

Expert Analysis and Recommendations

Synthesis of Risk-Benefit Profile

Orphenadrine is a pharmacologically complex agent with modest but documented efficacy for its primary indications of acute musculoskeletal pain and, to a lesser extent, parkinsonian motor symptoms. Its therapeutic utility is significantly constrained by a narrow therapeutic window, a predictable and burdensome anticholinergic side effect profile, and a high risk of severe, often fatal, toxicity in overdose. The benefits of its use must be carefully weighed against these substantial risks on a case-by-case basis.

Place in Therapy

In contemporary clinical practice, orphenadrine should not be considered a first-line agent for musculoskeletal pain. Its use is most appropriately reserved for short-term, adjunctive therapy in patients who have not responded to, or have contraindications to, safer alternatives such as NSAIDs or acetaminophen alone. The drug's unique multi-modal action, particularly its NMDA receptor antagonism, may provide a therapeutic advantage in select patients with complex pain syndromes that involve a component of central sensitization. However, this potential benefit must be carefully evaluated against its well-established risks. Its role in Parkinson's disease is now limited to niche situations where its anticholinergic effects are specifically desired and can be tolerated by the patient.

Recommendations for Prescribers

To ensure the safe use of orphenadrine, the following recommendations are critical:

• Patient Selection: Meticulous patient screening is paramount. Use should be avoided in elderly patients whenever possible due to the heightened risks of confusion, falls, and long-term cognitive decline. Prescribers must strictly adhere to all contraindications, with particular attention to glaucoma, prostatic hypertrophy, and any obstructive gastrointestinal or genitourinary conditions.
• Dosing and Duration: Therapy should be initiated at the lowest effective dose and prescribed for the shortest possible duration to achieve the therapeutic goal. Continuous long-term therapy is not recommended, as its safety has not been established.
• Monitoring: For any patient on prolonged therapy, periodic monitoring of blood counts, liver function, and renal function is a prudent measure, as recommended in official prescribing information.[5]
• Patient Counseling: Comprehensive patient education is essential and must cover several key points:
• The high likelihood of experiencing anticholinergic side effects (e.g., dry mouth, drowsiness, dizziness) and strategies for their management.
• The absolute contraindication of consuming alcohol while taking the medication.
• The potential for impairment of cognitive and motor skills and the associated danger of driving or operating heavy machinery.
• The significant danger of overdose and the critical importance of keeping the medication securely stored and out of the reach of children and others.
• The necessity of informing the prescriber of all other medications being taken, including over-the-counter drugs and supplements, to avoid potentially dangerous additive anticholinergic or CNS depressant effects.

Future Directions

The neuroprotective potential of orphenadrine mediated by its NMDA receptor antagonism is a scientifically interesting avenue that may warrant further investigation. However, a more viable path forward would likely involve the development of novel agents that target this mechanism with a more favorable safety profile, rather than expanding the clinical use of orphenadrine itself. The ongoing clinical studies in bruxism and the positive pilot data in cirrhosis-related muscle cramps suggest that orphenadrine's complex pharmacology may yet hold value in niche, difficult-to-treat conditions, provided its use is confined to specialist supervision and carefully selected patient populations.

Works cited

1. Orphenadrine - Wikipedia, accessed November 1, 2025, https://en.wikipedia.org/wiki/Orphenadrine
2. Orphenadrine - LiverTox - NCBI Bookshelf - NIH, accessed November 1, 2025, https://www.ncbi.nlm.nih.gov/books/NBK548850/
3. Orphenadrine (oral route) - Side effects & dosage - Mayo Clinic, accessed November 1, 2025, https://www.mayoclinic.org/drugs-supplements/orphenadrine-oral-route/description/drg-20065214
4. Orphenadrine: MedlinePlus Drug Information, accessed November 1, 2025, https://medlineplus.gov/druginfo/meds/a682162.html
5. Norflex™ - accessdata.fda.gov, accessed November 1, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/012157s028lbl.pdf
6. www.mayoclinic.org, accessed November 1, 2025, https://www.mayoclinic.org/drugs-supplements/orphenadrine-oral-route/description/drg-20065214#:~:text=Orphenadrine%20is%20used%20to%20help,trembling%20caused%20by%20Parkinson's%20disease.
7. Orphenadrine: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed November 1, 2025, https://go.drugbank.com/drugs/DB01173
8. Orphenadrine | C18H23NO | CID 4601 - PubChem, accessed November 1, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Orphenadrine
9. Orphenadrine | 83-98-7 - ChemicalBook, accessed November 1, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1397020.htm
10. Orphenadrine) | NMDA Antagonist | MedChemExpress, accessed November 1, 2025, https://www.medchemexpress.com/orphenadrine.html
11. Orphenadrine – Knowledge and References – Taylor & Francis, accessed November 1, 2025, https://www.taylorandfrancis.com/knowledge/Medicine_and_healthcare/Pharmaceutical_medicine/Orphenadrine/
12. 1.8. Orphenadrine | Therapeutic Goods Administration (TGA), accessed November 1, 2025, https://www.tga.gov.au/resources/publication/scheduling-decisions-interim/scheduling-delegates-interim-decisions-and-invitation-further-comment-accsacms-november-2017/18-orphenadrine
13. AMA submission to ACMS re orphenadrine downscheduling proposal, accessed November 1, 2025, https://ama.com.au/sites/default/files/documents/AMA_submission_orphenadrine_downscheduling_proposal_Sep17.pdf
14. 1.8 Orphenadrine | Therapeutic Goods Administration (TGA), accessed November 1, 2025, https://www.tga.gov.au/resources/publication/scheduling-decisions-final/final-decisions-amending-or-not-amending-current-poisons-standard-april-2018/18-orphenadrine
15. Orphenadrine Recruiting Phase 4 Trials for Bruxism / Pain, Orofacial Treatment - DrugBank, accessed November 1, 2025, https://go.drugbank.com/drugs/DB01173/clinical_trials?conditions=DBCOND0010734%2CDBCOND0105081&phase=4&purpose=treatment&status=recruiting
16. Pilot study of orphenadrine as a novel treatment for muscle cramps ..., accessed November 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5949967/
17. orphenadrine | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed November 1, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7251
18. Orphenadrine - the NIST WebBook - National Institute of Standards and Technology, accessed November 1, 2025, https://webbook.nist.gov/cgi/cbook.cgi?ID=83-98-7
19. Orphenadrine - brand name list from Drugs.com, accessed November 1, 2025, https://www.drugs.com/ingredient/orphenadrine.html
20. Orphenadrine | The Merck Index Online, accessed November 1, 2025, https://merckindex.rsc.org/monographs/m8245
21. (±)-Orphenadrine - CAS Common Chemistry, accessed November 1, 2025, https://commonchemistry.cas.org/detail?cas_rn=83-98-7
22. ORPHENADRINE - precisionFDA, accessed November 1, 2025, https://precision.fda.gov/ginas/app/ui/substances/c01cad47-4f10-4d2b-a1eb-15f301406b1f
23. 40249 Orphenadrine Citrate Final Print Label - Amazon S3, accessed November 1, 2025, https://s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB01173.pdf?1265922806
24. Orphenadrine Citrate - Antiparkinsonian & Analgesic Agent | APExBIO, accessed November 1, 2025, https://www.apexbt.com/orphenadrine-citrate.html
25. PRODUCT INFORMATION - Cayman Chemical, accessed November 1, 2025, https://caymanchem.com/pdfs/26391.pdf
26. Orphenadrine Citrate Datasheet - Selleck Chemicals, accessed November 1, 2025, https://www.selleckchem.com/datasheet/orphenadrine-citrate-norflex-S205401-DataSheet.html
27. Orphenadrine = 98.0 AT 341-69-5 - Sigma-Aldrich, accessed November 1, 2025, https://www.sigmaaldrich.com/US/en/product/aldrich/75517
28. en.wikipedia.org, accessed November 1, 2025, https://en.wikipedia.org/wiki/Orphenadrine#:~:text=Orphenadrine%20is%20often%20available%20mixed,Disipal%20is%20the%20hydrochloride%20salt.
29. Orphenadrine Citrate | C24H31NO8 | CID 83823 - PubChem, accessed November 1, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Orphenadrine-Citrate
30. ORPHENADRINE CITRATE - precisionFDA, accessed November 1, 2025, https://precision.fda.gov/ginas/app/ui/substances/X0A40N8I4S
31. Orphenadrine; Aspirin; Caffeine Tablets - Cleveland Clinic, accessed November 1, 2025, https://my.clevelandclinic.org/health/drugs/21237-orphenadrine-aspirin-caffeine-tablets
32. PARACETAMOL ORPHENADRINE Citrate - FDA Verification Portal, accessed November 1, 2025, https://verification.fda.gov.ph/files/DRP-11746-01_PI_01.pdf
33. NORGESIC paracetamol orphenadrine citrate blister pack (156623 ..., accessed November 1, 2025, https://www.tga.gov.au/resources/artg/156623
34. Orphenadrine Monograph for Professionals - Drugs.com, accessed November 1, 2025, https://www.drugs.com/monograph/orphenadrine.html
35. Orphenadrine Citrate Extended-Release Tablets(100 mg) - DailyMed, accessed November 1, 2025, https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6e89e43d-a3fc-481e-8aed-d6955fa2a14b
36. medlineplus.gov, accessed November 1, 2025, https://medlineplus.gov/druginfo/meds/a682162.html#:~:text=Orphenadrine%20is%20in%20a%20class,the%20body%20senses%20muscle%20pain.
37. Orphenadrine prevents 3-nitropropionic acid-induced neurotoxicity ..., accessed November 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC1572610/
38. NORFLEX™ - Medsafe, accessed November 1, 2025, https://www.medsafe.govt.nz/consumers/cmi/n/Norflex.pdf
39. australian product information – norflex (orphenadrine citrate) slow release tablets 1 name of the medicine - Medsinfo, accessed November 1, 2025, https://rss.medsinfo.com.au/ia/pi.cfm?product=iapnorfx
40. Orphenadrine – Knowledge and References - Taylor & Francis, accessed November 1, 2025, https://taylorandfrancis.com/knowledge/Medicine_and_healthcare/Pharmaceutical_medicine/Orphenadrine/
41. orphenadrine citrate - NCI Drug Dictionary - National Cancer Institute, accessed November 1, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/orphenadrine-citrate
42. Norgesic (orphenadrine citrate, aspirin and ... - accessdata.fda.gov, accessed November 1, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/013416s030lbl.pdf
43. Focus on: Orphenadrine citrate as a muscle relaxant - African Journals Online, accessed November 1, 2025, https://www.ajol.info/index.php/safp/article/view/234387/221394
44. Orphenadrine Hydrochloride 50mg/5ml Oral Solution - Summary of ..., accessed November 1, 2025, https://www.medicines.org.uk/emc/product/6691/smpc
45. (PDF) In-Silico Study of Diphenhydramine and Orphenadrine Binding Affinities to H1 and NMDA Receptors: Implications for Pharmacological Effects - ResearchGate, accessed November 1, 2025, https://www.researchgate.net/publication/391226491_In-Silico_Study_of_Diphenhydramine_and_Orphenadrine_Binding_Affinities_to_H1_and_NMDA_Receptors_Implications_for_Pharmacological_Effects
46. Norflex (orphenadrine citrate) Injection [Graceway Pharmaceuticals, LLC] Effective Date - accessdata.fda.gov, accessed November 1, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/013055s021lbl.pdf
47. NORFLEX, accessed November 1, 2025, https://pdf.hres.ca/dpd_pm/00015942.PDF
48. NEW ZEALAND DATA SHEET NORFLEXTM - Medsafe, accessed November 1, 2025, https://www.medsafe.govt.nz/profs/datasheet/n/Norflextabinj.pdf
49. Orphenadrine: Drug information, accessed November 1, 2025, https://doctorabad.com/uptodate/d/topic.htm?path=orphenadrine-drug-information
50. A randomized single-dose, two-period crossover bioequivalence study of two fixed-dose Paracetamol/Orphenadrine combination preparations in healthy volunteers under fasted condition - PubMed Central, accessed November 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7310552/
51. orphenadrine citrate ER 100 mg tablet,extended release | Kaiser Permanente, accessed November 1, 2025, https://healthy.kaiserpermanente.org/health-wellness/drug-encyclopedia/drug.orphenadrine-citrate-er-100-mg-tablet-extended-release.252046
52. Orphengesic Forte (orphenadrine/aspirin/caffeine) dosing, indications, interactions, adverse effects, and more - Medscape Reference, accessed November 1, 2025, https://reference.medscape.com/drug/orphengesic-forte-orphenadrine-aspirin-caffeine-1000363
53. Norflex - Healthdirect, accessed November 1, 2025, https://www.healthdirect.gov.au/medicines/brand/amt,35941011000036107/norflex
54. Postoperative pain Completed Phase 4 Trials for Orphenadrine (DB01173) - DrugBank, accessed November 1, 2025, https://go.drugbank.com/indications/DBCOND0022333/clinical_trials/DB01173?phase=4&status=completed
55. Norflex (DSC) (orphenadrine) dosing, indications, interactions, adverse effects, and more, accessed November 1, 2025, https://reference.medscape.com/drug/norflex-orphenadrine-343344
56. Orphenadrine | Side Effects, Dosage, Uses, and More - Healthline, accessed November 1, 2025, https://www.healthline.com/health/drugs/orphenadrine-oral-tablet
57. Approval - accessdata.fda.gov, accessed November 1, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/anda/98/75141ap.pdf
58. Norflex - Drug Summary, accessed November 1, 2025, https://www.pdr.net/drug-summary/Orphenadrine-Citrate-Injection-orphenadrine-citrate-3060
59. Orphenadrine Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed November 1, 2025, https://www.drugs.com/dosage/orphenadrine.html
60. Orphenadrine: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed November 1, 2025, https://www.rxlist.com/orphenadrine/generic-drug.htm
61. Orphenadrine - Memorial Sloan Kettering Cancer Center, accessed November 1, 2025, https://www.mskcc.org/cancer-care/patient-education/medications/adult/orphenadrine
62. Orphenadrine tablets - Cleveland Clinic, accessed November 1, 2025, https://my.clevelandclinic.org/health/drugs/20288-orphenadrine-tablets
63. Orphenadrine: Uses, Side Effects, Interactions & More - GoodRx, accessed November 1, 2025, https://www.goodrx.com/orphenadrine-er/what-is
64. Valium vs. Norflex for Musculoskeletal Conditions: Important Differences and Potential Risks. - GoodRx, accessed November 1, 2025, https://www.goodrx.com/compare/valium-vs-norflex
65. Orphenadrine w/A.C. Advanced Patient Information - Drugs.com, accessed November 1, 2025, https://www.drugs.com/cons/orphenadrine-w-a-c.html
66. Orphenadrine Citrate - DailyMed, accessed November 1, 2025, https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8a258480-2f47-4b62-850c-1beed383ba29&type=display
67. Orphenadrine: Uses, Side Effects, Dosage & Interactions - Apollo Hospitals, accessed November 1, 2025, https://www.apollohospitals.com/medicines/orphenadrine
68. Orphenadrine Side Effects: Common, Severe, Long Term - Drugs.com, accessed November 1, 2025, https://www.drugs.com/sfx/orphenadrine-side-effects.html
69. Orphenadrine Uses, Side Effects & Warnings - Drugs.com, accessed November 1, 2025, https://www.drugs.com/mtm/orphenadrine.html
70. www.mayoclinic.org, accessed November 1, 2025, https://www.mayoclinic.org/drugs-supplements/orphenadrine-oral-route/description/drg-20065214#:~:text=This%20medicine%20may%20cause%20some,muscle%20weakness%20in%20some%20people.
71. Restriction to the use of orphenadrine, accessed November 1, 2025, https://www.hpft.nhs.uk/media/1949/orphenadrine-briefing-note-no-3-updated-march-2016.pdf
72. Full recovery from a potentially lethal dose of orphenadrine ingestion using conservative treatment: a case report - PubMed, accessed November 1, 2025, https://pubmed.ncbi.nlm.nih.gov/20200196/
73. Clinical outcomes associated with orphenadrine deliberate self-poisoning: a retrospective poisons centre study - PubMed, accessed November 1, 2025, https://pubmed.ncbi.nlm.nih.gov/38525870/
74. Orphenadrine Interactions Checker - Drugs.com, accessed November 1, 2025, https://www.drugs.com/drug-interactions/orphenadrine.html
75. Norflex Interactions Checker - Drugs.com, accessed November 1, 2025, https://www.drugs.com/drug-interactions/orphenadrine,norflex.html
76. Orphenadrine and Alcohol/Food Interactions - Drugs.com, accessed November 1, 2025, https://www.drugs.com/food-interactions/orphenadrine.html
77. Orphenadrine Citrate Er Food, Alcohol, Supplements and Drug Interactions, accessed November 1, 2025, https://www.wellrx.com/orphenadrine-citrate-er/lifestyle-interactions/
78. Alcohol And Muscle Relaxers Shouldn't Be Mixed. Here's Why - GoodRx, accessed November 1, 2025, https://www.goodrx.com/classes/muscle-relaxants/alcohol-and-muscle-relaxers
79. Orphenadrine Disease Interactions - Drugs.com, accessed November 1, 2025, https://www.drugs.com/disease-interactions/orphenadrine.html
80. Anticholinergic drugs: Uses and side effects - Medical News Today, accessed November 1, 2025, https://www.medicalnewstoday.com/articles/323514
81. Combined levodopa-anticholinergic therapy in the treatment of Parkinson's disease. Effect on levodopa bioavailability - PubMed, accessed November 1, 2025, https://pubmed.ncbi.nlm.nih.gov/2015611/
82. Determination That NORFLEX (Orphenadrine Citrate) Injection, 30 Milligrams/Milliliter, and NORFLEX (Orphenadrine Citrate) Extended-Release Tablet, 100 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness - Federal Register, accessed November 1, 2025, https://www.federalregister.gov/documents/2022/12/08/2022-26663/determination-that-norflex-orphenadrine-citrate-injection-30-milligramsmilliliter-and-norflex
83. Drug Approval Package: Orphenadrine NDA #040249, accessed November 1, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/anda/99/040249_orphenadrine_toc.cfm
84. FDA Approves Sagent Pharmaceuticals' Orphenadrine Citrate Injection, USP, accessed November 1, 2025, https://firstwordpharma.com/story/1301685
85. FDA approves orphenadrine - Managed Healthcare Executive, accessed November 1, 2025, https://www.managedhealthcareexecutive.com/view/fda-approves-orphenadrine
86. Norgesic - NPS MedicineWise, accessed November 1, 2025, https://www.nps.org.au/medicine-finder/norgesic-tablets
87. NORFLEX orphenadrine citrate 100 mg slow release tablet blister ..., accessed November 1, 2025, https://www.tga.gov.au/resources/artg/370413
88. European Medicines Agency (EMA), accessed November 1, 2025, https://www.ema.europa.eu/en/medicines
89. EMEA-003337-PIP01-22 - paediatric investigation plan | European ..., accessed November 1, 2025, https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003337-pip01-22
90. Sandoz, Inc. Issues Nationwide Recall of 13 Lots of Orphenadrine Citrate 100 mg Extended Release Tablets Due to Presence of a Nitrosamine Impurity | FDA, accessed November 1, 2025, https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sandoz-inc-issues-nationwide-recall-13-lots-orphenadrine-citrate-100-mg-extended-release-tablets-due